Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 14/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 2/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526567 | 0.86 | PDK2 (0.41) | PDK2PDK4CCNT1CDK9IKBKB | |
| SCHEMBL90961 | 0.86 | GRIA2 (0.42) | GRIA2CYP2C19PDK2PDK4CCNT1 | |
| SCHEMBL8553204 | 0.81 | GRIA2 (0.45) | GRIA2CYP2C19CYP1A2 | |
| SCHEMBL90942 | 0.76 | PDK2 (0.38) | PDK2PDK4CDK9IKBKBCHUK | |
| SCHEMBL90850 | 0.72 | PDK2 (0.43) | PDK2PDK4CDK9CLK2DYRK1A | |
| SCHEMBL8596030 | 0.70 | PDK2 (0.39) | PDK2PDK4CDK9IKBKBCHUK | |
| SCHEMBL90911 | 0.69 | SMO (0.36) | PDK2PDK4 | |
| SCHEMBL8554483 | 0.69 | PDK2 (0.37) | PDK2PDK4 | |
| SCHEMBL90978 | 0.69 | DRD4 (0.48) | GRIA2CYP1A2 | |
| SCHEMBL3254498 | 0.69 | GRIA2 (0.71) | GRIA2CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | GRIA2 634/4885CYP2C19 1933/4885PDK2 3734/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | GRIA2 634/4885CYP2C19 1933/4885PDK2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.